Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment
- 14 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Heart Failure Reviews
- Vol. 26 (5), 1159-1173
- https://doi.org/10.1007/s10741-020-09968-2
Abstract
Anthracycline is a mainstay in treatment of many cancers including lymphoma and breast cancer among many others. However, anthracycline treatment can be cardiotoxic. Although anthracycline-induced cardiotoxicity is dose dependent, it can also occur early at the onset of treatment and even up to several years following completion of treatment. This review article focuses on the understanding of mechanisms of anthracycline-induced cardiotoxicity, the treatments, and recommended follow-up and preventive approaches.Keywords
This publication has 98 references indexed in Scilit:
- Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control studyInternational Journal of Cardiology, 2013
- Normal Ranges of Left Ventricular Strain: A Meta-AnalysisJournal of the American Society of Echocardiography, 2013
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trialThe Lancet, 2011
- Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patientsBritish Journal of Cancer, 2011
- Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?Progress in Cardiovascular Diseases, 2010
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?Clinical Chemistry, 2005
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004